Exactly. Avastin was reviewed in the UK for colorectal cancer, and NICE came to the conclusion that it is not a cost-effective treatment. https://www.theguardi

Exactly. Avastin was reviewed in the UK for colorectal cancer, and NICE came to the conclusion that it is not a cost-effective treatment. https://www.theguardian.com/society/2010/aug/24/avastin-too-expensive-for-patients https://www.theguardian.com/society/2010/aug/24/avastin-too-... Long story, it costs more than the national minimum wage, and on average improves the life expectancy by only 7% compared to chemotherapy without Avastin (21.3 months vs 19.9 months). Fundamentally though the sticking point is the cost. The article also says: > Data also suggests the trio of drugs means the liver tumours of 78% of patients shrink to such a degree that they are eligible for potentially life-saving surgery. But this seems to be limited to liver tumours, not colorectal tumours, and it doesn't give any success rate for the surgery. The implication is that the liver tumours were previously too large to operate on, but that's not clear.